Stoke Therapeutics names Solid Biosciences CEO Bo Cumbo to board
STOK•Cumbo's background
Cumbo has led rare-disease commercial launches; he is CEO and a director at Solid Biosciences.
He previously held senior commercial roles at Sarepta Therapeutics, including chief commercial officer, with earlier roles at Vertex and Gilead.
Board appointment and director retirement
Stoke Therapeutics appointed Bo Cumbo to its board.
Edward Kaye retired as a director; he served on the board since 2017 and was CEO from 2017 to March 2025.
